Bain invests $300M in Boston cardiovascular disease firm

Bain Capital is investing up to $300 million into Cardurion Pharmaceuticals Inc. from both its Bain Capital Life Sciences and Bain Capital Private Equity funds.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.